Escalade, a leading sporting goods manufacturer, will announce its third quarter 2026 financial results on October 29 before market open. The company will host a conference call at 11:00 a.m. ET the same day to discuss the results and answer investor questions. This update is important for investors tracking Escalade's performance and strategic focus on its sporting goods business. The call will be accessible via webcast on Escalade's website and by phone, with replays available until November 12, 2026.
Escalade's upcoming third quarter 2026 results announcement is noted alongside Pluang's Consumer Cyclical sector market data. For readers following this sector, here is Pluang's market snapshot as of Oct 23, 2026 03:21 WIB: out of 134 priced US stocks, 94 rose and 40 fell. Notable movements include GTX at USD 21.86 with a -8.65% change and a typical hold time of 14 days, RENT at USD 2.36 with an 8.26% increase and 92% sell order activity, and LEN at USD 83.71 with a 7.73% rise and 100% sell order activity.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Lycia Therapeutics, a biotech company developing therapies targeting disease-causing proteins, priced its upsized initial public offering at $18 per share, raising approximately $317.5 million before expenses. The company plans to use the funds to ad...
